Chitosan nanoparticles as non-viral gene delivery systems: Determination of loading efficiency

Biomedicine and Pharmacotherapy

Volumn 68, Issue 6, 2014, Pages 775-783

  Carrillo, Carolina ^a   Suñé, Josep Maria ^a   Pérez Lozano, Pilar ^a   García Montoya, Encarna ^a   Sarrate, Rocío ^a   Fàbregas, Anna ^a   Miñarro, Montserrat ^a   Ticó, Josep Ramon ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chitosan; Gene therapy; Nanoparticles; Non viral vector; Particle delivery systems; Polyplexes

Indexed keywords

CHITOSAN DERIVATIVE; CHITOSAN NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; CHITOSAN;

ADSORPTION; AGAR GEL ELECTROPHORESIS; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; GELATION; LASER DIFFRACTION; LIGHT SCATTERING; MOLECULAR WEIGHT; NANOENCAPSULATION; NONVIRAL GENE DELIVERY SYSTEM; SURFACE CHARGE; ZETA POTENTIAL; CHEMISTRY; GENE THERAPY; GENE TRANSFER; PROCEDURES; TRENDS;

CHITOSAN; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; NANOPARTICLES;

EID: 84908090406     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.07.009     Document Type: Article

References (60)

1. Corsi K., Chellat F., Yahia L., Fernandes J.C. Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials 2003, 24:1255-1264. 10.1016/S0142-9612(02)00507-0.
2. Ledley F.D. Pharmaceutical approach to somatic gene therapy. Pharm Res 1996, 13:1595-1614.
3. Nishikawa M., Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull 2002, 25:275-283.
4. Davis M.E. Non-viral gene delivery systems. Curr Opin Biotechnol 2002, 13(2):128-131.
5. Ramos V.M., Rodríguez N.M., Rodríguez M.S., Heras A., Agulló E. Modified chitosan carrying phosphonic and alkyl groups. Carbohydr Polym 2003, 51(4):425-429.
6. Ewert K., Ahmad A., Evans H.M., Safinya C.R. Cationic lipid-DNA complexes for non-viral gene therapy: relating supramolecular structures to cellular pathways. Expert Opin Biol Ther 2005, 5(1):33-53.
7. Li S., Huang L. Non-viral is superior to viral gene delivery. J Control Release 2007, 123(3):181-183.
8. Ferrer-Miralles N., Vázquez E., Villaverde A. Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol 2008, 26(5):267-275.
9. He C., Tabata Y., Gao J. Non-viral gene delivery carrier and its three-dimensional transfection system. Int J Pharm 2010, 386(1-2):232-242.
10. Rogers M.L., Rush R.A. Non-viral gene therapy for neurological diseases, with an emphasis on targeted gene delivery. J Control Release 2012, 157:183-189. 10.1016/j.jconrel.2011.08.026.
11. Liang Y., Liu Z., Shuai X., Wang W., Liu J., Bi W., et al. Delivery of cationic polymer-siRNA nanoparticles for gene therapies in neural regeneration. Biochem Biophys Res Commun 2012, 421:690-695. 10.1016/j.bbrc.2012.03.155.
12. Faneca H., Simões S., Pedroso de Lima M.C. Evaluation of lipid-based reagents to mediate intracellular gene delivery. Biochim Biophys Acta 2002, 1567:23-33.
13. Mansouri S., Lavigne P., Corsi K., Benderdour M., Beaumont E., Fernandes J.C. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur J Pharm Biopharm 2004, 57(1):1-8.
14. Pedersen N., Hansen S., Heydenreich A.V., Kristensen H.G., Poulsen H.S. Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur J Pharm Biopharm 2006, 62(2):155-162.
15. del Pozo-Rodríguez A., Delgado D., Solinís M.A., Gascón A.R., Pedraz J.L. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int J Pharm 2007, 339(1-2):261-268.
16. Carrillo C., Sánchez-Hernández N., García-Montoya E., Pérez-Lozano P., Suñé-Negre J.M., Ticó J.R., et al. DNA delivery via cationic solid lipid nanoparticles (SLNs). Eur J Pharm Sci 2013, 49:157-165. 10.1016/j.ejps.2013.02.011.
17. Storrie H., Mooney D.J. Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. Adv Drug Deliv Rev 2006, 58(4):500-514.
18. Gao X., Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry 1996, 35(3):1027-1036.
19. Singla A.K., Chawla M. Chitosan: some pharmaceutical and biological aspects-an update. J Pharm Pharmacol 2001, 53(8):1047-1067.
20. Kas H.S. Chitosan: properties, preparation and application to microparticulate systems. J Microencapsulation 1997, 14:689-711.
21. Pillai C.K.S., Paul W., Sharma C.P. Chitin and chitosan polymers: chemistry, solubility and fiber formation. Prog Polym Sci 2009, 34(7):641-678.
22. Aspden T.J., Illum L., Skaugrud Ø. Chitosan as a nasal delivery system: evaluation of insulin absorption enhancement and effect on nasal membrane integrity using rat models. Eur J Pharm Sci 1996, 4(1):23-31.
23. Fernandez-Urrusuno R., Calvo P., Remunan-Lopez C., Vila-Jato J.L., Alonso M.J. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 1999, 16(10):1576.
24. De Campos A.M., Sánchez A., Alonso M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface, Application to cyclosporin A. Int J Pharm 2001, 224(1-2):159-168.
25. Guang Liu W., De Yao K. Chitosan and its derivatives-a promising non-viral vector for gene transfection. J Control Release 2002, 83(1):1-11.
26. Yu S., Zhao Y., Wu F., Zhang X., Lü W., Zhang H. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. Int J Pharm 2004, 281(1-2):11-23.
27. 2 cells: the influence of chitosans of different molecular weights and degrees of acetylation. J Pharm Pharmacol 2006, 58(7):909-915.
28. Garcia-Fuentes M., Alonso M.J. Chitosan-based drug nanocarriers: where do we stand?. J Control Release 2012, 161:496-504. 10.1016/j.jconrel.2012.03.017.
29. Mumper R.J., Duguid J.G., Anwer K., Barron M.K., Nitta H., Rolland A.P. Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle. Pharm Res 1996, 13(5):701-709. 05-01.
30. Mitra S., Gaur U., Ghosh P.C., Maitra A.N. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001, 74(1-3):317-323.
31. Janes K.A., Calvo P., Alonso M.J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev 2001, 47(1):83-97.
32. Gao S., Chen J., Dong L., Ding Z., Yang Y., Zhang J. Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector. Eur J Pharm Biopharm 2005, 60(3):327-334.
33. Katas H., Alpar H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 2006, 115(2):216-225.
34. Howard K.A., Rahbek U.L., Liu X., Damgaard C.K., Glud S.Z., Andersen M.O. RNA interference in vitro and in vivo using a chitosan/siRNA nanoparticle system. Mol Ther 2006, 14(4):476-484.
35. Zhang S., Zhao B., Jiang H., Wang B., Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 2007, 123(1):1-10.
36. Puras G., Zarate J., Aceves M., Murua A., Díaz A.R., Avilés-Triguero M., et al. Low molecular weight oligochitosans for non-viral retinal gene therapy. Eur J Pharm Biopharm 2013, 83:131-140. 10.1016/ejpb.2012.09.010.
37. MacLaughlin F.C., Mumper R.J., Wang J., Tagliaferri J.M., Gill I., Hinchcliffe M., et al. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release 1998, 56(1-3):259-272.
38. Richardson S.C.W., Kolbe H.V.J., Duncan R. Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm 1999, 178(2):231-243.
39. Mao S., Shuai X., Unger F., Simon M., Bi D., Kissel T. The depolymerization of chitosan: effects on physicochemical and biological properties. Int J Pharm 2004, 281(1-2):45-54.
40. Gan Q., Wang T., Cochrane C., McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf, B: Biointerf 2005, 44(2-3):65-73.
41. Calvo P., Remuñán-López C., Vila-Jato J.L., Alonso M.J. Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions. Colloid Polym Sci 1997, 275(1):46-53.
42. Sinha V.R., Singla A.K., Wadhawan S., Kaushik R., Kumria R., Bansal K., et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 2004, 274(1-2):1-33.
43. Csaba N., Köping-Höggård M., Alonso M.J. Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. Int J Pharm 2009, 382(1-2):205-214.
44. Mi F., Sung H., Shyu S., Su C., Peng C. Synthesis and characterization of biodegradable TPP/genipin co-crosslinked chitosan gel beads. Polymer 2003, 44(21):6521-6530.
45. Xu Y., Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 2003, 250(1):215-226.
46. Vila A., Sánchez A., Janes K., Behrens I., Kissel T., Jato J.L.V., et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 2004, 57(1):123-131.
47. López-León T., Carvalho E.L.S., Seijo B., Ortega-Vinuesa J.L., Bastos-González D. Physicochemical characterization of chitosan nanoparticles: electrokinetic and stability behavior. J Colloid Interf Sci 2005, 283(2):344-351.
48. Aktas Y., Andrieux D., Alonso M.J., Calvo P., Gürsoy R.N., Couvreur P., et al. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm 2005, 298:378-383.
49. Krauland A.H., Alonso M.J. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Int J Pharm 2007, 340(1-2):134-142.
50. Shu X.Z., Zhu K.J. A novel approach to prepare tripolyphosphate/chitosan complex beads for controlled release drug delivery. Int J Pharm 2000, 201(1):51-58.
51. Papadimitriou S., Bikiaris D., Avgoustakis K., Karavas E., Georgarakis M. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym 2008, 73(1):44-54. 7/4.
52. Fàbregas A., Miñarro M., García-Montoya E., Pérez-Lozano P., Carrillo C., Sarrate R., et al. Impact of physical parameters on particle size and reaction yield when using the ionic gelation method to obtain cationic polymeric chitosan-tripolyphosphate nanoparticles. Int J Pharm 2013, 446(1-2):199-204. 10.1016/j.ijpharm.2013.02.015.
53. Dong Y., Ng W.K., Shen S., Kim S., Tan R.B.H. Scalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixers. Carbohydr Polym 2013, 94:940-945. 10.1016/j.carbpol.2013.02.013.
54. Dehousse V., Garbacki N., Jaspart S., Castagne D., Piel G., Colige A., et al. Comparison of chitosan/siRNA and trimethylchitosan/siRNA complexes behaviour in vitro. Int J Biol Macromol 2010, 46(3):342-349. 4/1.
55. Gan Q., Wang T. Chitosan nanoparticle as protein delivery carrier-systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B: Biointerf 2007, 59(1):24-34. 9/1.
56. Suñé C., Hayashi T., Liu Y., Lane W.S., Young R.A., Garcia-Blanco M.A. CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated HIV-1 transcription. Mol Cell Biol 1997, 17:6029-6039.
57. Liu X., Howard K.A., Dong M., Andersen M.Ø., Rahbek U.L., Johnsen M.G., et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 2007, 28(6):1280-1288. 2.
58. Lee S.H., Mok H., Park T.G. Di- and triblock siRNA-PEG copolymers: peg density effect of polyelectrolyte complexes on cellular uptake and gene silencing efficiency. Macromol Biosci 2011, 11(3):410-418.
59. Yang X., Yuan X., Cai D., Wang S., Zong L. Low molecular weight chitosan in DNA vaccine delivery via mucosa. Int J Pharm 2009, 375(1-2):123-132.
60. Yang H., Hon M. The effect of the molecular weight of chitosan nanoparticles and its application on drug delivery. Microchem J 2009, 92(1):87-91.